A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B‐cell lymphoma

A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B‐cell lymphoma

Histone deacetylase (HDAC) inhibitors such as suberoylanilide hydroxamic acid (SAHA) are not commonly used in clinical practice for treatment of B‐cell lymphomas, although a subset of patients with refractory or relapsed B‐cell lymphoma achieved partial or complete remissions. Therefore, the purpose...

Full description

Bibliographic Details
Main Authors: Maria Joosten, Sebastian Ginzel, Christian Blex, Dmitri Schmidt, Michael Gombert, Cai Chen, René Martin Linka, Olivia Gräbner, Anika Hain, Burkhard Hirsch, Anke Sommerfeld, Anke Seegebarth, Uschi Gruber, Corinna Maneck, Langhui Zhang, Katharina Stenin, Henrik Dieks, Michael Sefkow, Carsten Münk, Claudia D. Baldus, Ralf Thiele, Arndt Borkhardt, Michael Hummel, Hubert Köster, Ute Fischer, Mathias Dreger, Volkhard Seitz
Format: Article
Language:English
Published: Wiley 2016-10-01
Series:Molecular Oncology
Subjects:
SAHA
HDAC inhibitor
FGR
B-cell lymphoma
Drug resistance
Online Access:https://doi.org/10.1016/j.molonc.2016.06.001

Internet

https://doi.org/10.1016/j.molonc.2016.06.001

Similar Items